Department of Medicine, The Royal Marsden NHS Foundation Trust, London and Surrey, United Kingdom.
Department of Medicine, The Royal Marsden NHS Foundation Trust, London and Surrey, United Kingdom.
Cancer Treat Rev. 2017 Sep;59:132-137. doi: 10.1016/j.ctrv.2017.07.009. Epub 2017 Aug 9.
After decades of intense research on genetic alterations in cancer and successful implementation of genetically-based targeted therapies, the field of cancer epigenetics is only beginning to be fully recognized. The discovery of frequent mutations in genes modifying the epigenome in diffuse large B-cell lymphoma (DLBCL) has highlighted the outstanding role of epigenetic deregulation in this disease. Identification of epigenetically-driven DLBCL subgroups and development of novel epigenetic drugs have rapidly advanced. However, further insights are needed into the biological consequences of epigenetic alterations and the possibility of restoring the aberrant epigenome with specific therapies to bring this treatment concept further into clinical practice. This review will summarize the main epigenetic changes found in DLBCL and their potential for precision medicine approaches.
经过几十年对癌症基因改变的深入研究和成功实施基于基因的靶向治疗，癌症表观遗传学领域才刚刚开始被全面认识。弥漫性大 B 细胞淋巴瘤（DLBCL）中修饰表观基因组的基因频繁突变的发现，突出了表观遗传失调在这种疾病中的突出作用。鉴定出受表观遗传驱动的 DLBCL 亚群并开发新型表观遗传药物已迅速取得进展。然而，我们还需要进一步深入了解表观遗传改变的生物学后果，以及是否有可能通过特定疗法恢复异常的表观基因组，从而将这种治疗概念进一步推向临床实践。本文将总结在 DLBCL 中发现的主要表观遗传变化及其在精准医疗方法中的潜在应用。
